Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab subcutaneous versus intravenous plus lenalidomide in relapsed or refractory follicular lymphoma
CTR20220324Phase 2Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, lenalidomide, glofitamab, obinutuzumab in follicular lymphoma (FL), sponsored by Roche. Started Mar 2022; status: active.
02
Drugs
mosunetuzumablenalidomideglofitamabobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20220324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220324.